biostudies-literatureUnknown9(5)Otowa-Suematsu N<h4>Introduction</h4>We comprehensively evaluated the effects of combination therapy with insulin glargine and the incretin-based drugs lixisenatide or vildagliptin in Japanese patients with type 2 diabetes.<h4>Methods</h4>In this 12-week, randomized, open-label, parallel-group, multicenter study (GLP-ONE Kobe), the incretin-based drug sitagliptin was randomly switched to lixisenatide (20 μg/day, n = 18) or vildagliptin (100 mg/day, n = 20) in patients with inadequate glycemic control despite combination therapy with insulin glargine and sitagliptin. The dose of insulin glargine was titrated after the switch to maintain fasting blood glucose at approximately 110 mg/dL. The primary end points of the study were the change in glycosylated hemoglobin (HbA_1c) level between before andDiabetes therapy : research, treatment and education of diabetes and related disorders2067-2079https://www.ebi.ac.uk/biostudies/studies/S-EPMC6167300biostudies-literatureComprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study.PMC6167300Kishi MYoshino HKomada HSakaguchi KTamori YOkada YKuroki YYokota KOgawa WHashimoto NHirota YNakamura THara KNishiumi TOtowa-Suematsu NSou AfalseComprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study.<h4>Introduction</h4>We comprehensively evaluated the effects of combination therapy with insulin glargine and the incretin-based drugs lixisenatide or vildagliptin in Japanese patients with type 2 diabetes.<h4>Methods</h4>In this 12-week, randomized, open-label, parallel-group, multicenter study (GLP-ONE Kobe), the incretin-based drug sitagliptin was randomly switched to lixisenatide (20 μg/day, n = 18) or vildagliptin (100 mg/day, n = 20) in patients with inadequate glycemic control despite combination therapy with insulin glargine and sitagliptin. The dose of insulin glargine was titrated after the switch to maintain fasting blood glucose at approximately 110 mg/dL. The primary end points of the study were the change in glycosylated hemoglobin (HbA_1c) level between before and2018-01-01T00:00:00Z2018 Oct2025-04-18T16:12:13.124Z2019-03-27T00:02:03ZS-EPMC61673003020690310.1007/s13300-018-0505-2